Open Access

CD271+ stromal cells expand in arthritic synovium and exhibit a proinflammatory phenotype

  • Manuel J. Del Rey1,
  • Regina Faré1,
  • Alicia Usategui1,
  • Juan D. Cañete2, 3,
  • Beatriz Bravo4,
  • María Galindo1,
  • Gabriel Criado1 and
  • José L. Pablos1Email author
Contributed equally
Arthritis Research & Therapy201618:66

https://doi.org/10.1186/s13075-016-0966-5

Received: 15 December 2015

Accepted: 29 February 2016

Published: 15 March 2016

Abstract

Background

CD271+ stromal cells (SCs) with multipotent stem cell capacity have been identified in synovial tissues, but their functional significance is unknown. We analyzed the distribution of CD271+ cells in inflammatory synovial tissues as well as their ex vivo immunomodulatory and inflammatory phenotypes.

Methods

CD271 expression was analyzed by immunohistochemistry in synovial tissues and by flow cytometry in primary adherent synovial cell cultures from rheumatoid arthritis (RA), osteoarthritis (OA), and non-inflammatory control tissues. Isolation of CD271+ synovial SCs was carried out by magnetic cell sorting. Allogeneic T-cell/SC cocultures were performed to analyze the regulatory capacity of these cells on T-cell proliferation and cytokine production. The production of inflammatory mediators was analyzed in cultures of sorted CD271+/ SCs. The capacity of CD271+/ SCs to induce inflammatory cell recruitment in vivo was evaluated in subcutaneous implants in immunodeficient mice.

Results

CD271+ SC were detected in non-inflammatory as well as in arthritic synovial tissues with a specific perivascular distribution. CD271+ SC density was increased in RA and OA compared with normal synovial tissues. T-cell proliferation and cytokine synthesis were similarly modified by CD271+ and CD271 SCs. Sorted CD271+ SCs from OA synovial tissues released significantly more interleukin (IL)-6, matrix metalloproteinase (MMP)-1, and MMP-3 than CD271 SCs. In immunodeficient mice, implants of CD271+ SCs induced significantly higher myeloid cell infiltration than CD271 SCs.

Conclusions

Our results demonstrate that CD271+ perivascular SCs expand in RA and OA synovial tissues. CD271+ cells showed enhanced proinflammatory properties ex vivo and in vivo, whereas immunoregulatory properties were equivalent in CD271+ and CD271 SC.

Keywords

Mesenchymal stem cellsStromal cellsSynovial fibroblastsRheumatoid arthritisOsteoarthritisNerve growth factor receptor

Background

The mesenchymal or stromal cell lineage in synovial tissue is represented by a heterogeneous population of stromal or fibroblastic cells, usually termed synovial fibroblasts (SFs) or type B synoviocytes. Under normal conditions, these cells contribute to the homeostasis of normal joints by synthesizing extracellular matrix components and secreting the specific components of synovial fluid [1]. SFs respond to inflammatory cytokines, notably tumor necrosis factor (TNF)-α, by producing a large variety of mediators of inflammation and tissue destruction [2, 3]. In chronic arthritis, SF hyperplasia and stable phenotypic changes also significantly contribute to the chronic inflammatory and destructive process [47].

SFs can be cultured as plastic adherent cells that express non-specific mesenchymal cell markers and lack myeloid and lymphoid lineage markers. However, SF cultures represent a heterogeneous cell mixture, as identified in synovial tissues by specific markers, and subpopulations are difficult to track under tissue culture conditions [4, 810]. Different synovial mesenchymal cell subtypes may have different differentiation and functional capacities that are difficult to analyze ex vivo.

Mesenchymal or stromal stem cells (MSCs) with multipotent differentiation potential and immunomodulatory activity have attracted strong interest as potential therapeutic agents [11, 12]. MSCs are abundant in the bone marrow (BM) as well as in most connective tissues, including synovial tissues [13, 14]. Because these cells lack specific markers, their identification in synovial tissues or SF cultures is difficult. CD271, also known as low-affinity nerve growth factor receptor (NGFR) or p75, identifies a subpopulation of stromal cells (SCs) with enhanced MSC differentiation capacities [15, 16]. Initially identified in the BM, CD271+ SC have subsequently been found in bone, adipose, and synovial tissues [1618]. Their local roles in joint physiology or in the pathogenesis of arthritis as immunomodulatory cells are unknown. Different studies have shown their potential contribution to cartilage repair ex vivo [16, 17, 19], but it is not known whether CD271+ synovial SCs can play immunomodulatory functions in arthritic inflammatory processes.

We examined the distribution and abundance of CD271+ SCs in synovial tissues from patients with rheumatoid arthritis (RA) or osteoarthritis (OA), and from control subjects without inflammation, as well as their ex vivo immunomodulatory and proinflammatory capacities compared with CD271 synovial adherent cells. We also analyzed their ability to induce inflammatory myeloid cell recruitment in vivo by engraftment in immunodeficient mice.

Methods

Ethical approval and consent to participate

This study was approved by the ethics committees of Hospital 12 de Octubre, Madrid, and Hospital Clìnic, Barcelona (Spain). All patients signed a written informed consent form. All animal experiments were carried out in accordance with institutional guidelines, and they were approved by the Hospital 12 de Octubre Animal Welfare Committee.

Patients and synovial biopsies

Synovial tissues were obtained by arthroscopic biopsy of the knees of patients diagnosed with RA with active knee arthritis (n = 10) [20]. OA synovial tissues were obtained at prosthetic joint replacement surgery (n = 10). Normal non-inflammatory synovial tissues were obtained from individuals without joint disease at elective arthroscopy for minor traumatic lesions (n = 6).

Immunolabeling

Synovial tissues were labeled by immunohistochemistry (IHC) using a standard peroxidase method (VECTASTAIN ABC Kit [standard]; Vector Laboratories, Burlingame, CA, USA) with anti-NGFR p75 (CD271) monoclonal antibody (mAb) (ME20.4 immunoglobulin G1 [IgG1]; Sigma-Aldrich, St. Louis, MO, USA) or mouse IgG1 isotype control (Sigma-Aldrich). Double-immunofluorescence (IF) labeling for CD271 and heat shock protein hsp47 (Assay Designs anti-hsp47 mAb M16.10A1 IgG2b; Enzo Life Sciences, Farmingdale, NY, USA) or CD31 (anti-CD31 rabbit mAb EPR3094 IgG; Abcam, Cambridge, UK) was performed using sequential incubation with isotype-specific Alexa Fluor 488 (green) or Alexa Fluor 594 (red) secondary antibodies (Molecular Probes/Life Technologies, Eugene, OR, USA). Counterstaining was done with hematoxylin or 4′,6-diamidino-2-phenylindole (DAPI) as indicated.

Frozen sections from mouse SC matrigel implants were also analyzed by IHC with an anti-human nuclei antibody (EMD Millipore, Temecula, CA, USA) or IF with phycoerythrin (PE)-labeled anti-CD11b (M1/70 IgG2b) or PE IgG2b control (BioLegend Inc., San Diego, CA, USA).

Photographs were obtained with Axioplan-2 fluorescence and LSM 510 META confocal microscopes (Carl Zeiss Microscopy, Jena, Germany). Quantitative data on CD271-stained fractional area and density of DAPI+ nuclei in matrigel sections were obtained from digitized images quantified using ImageJ software (http://rsb.info.nih.gov/ij; National Institutes of Health, Bethesda, MD, USA) as previously described [4].

Synovial SC cultures

Primary (passage 0) synovial adherent SCs were obtained by explant growth of synovial tissue fragments from surgical OA tissues in Dulbecco’s modified Eagle’s medium/10 % fetal calf serum (FCS) (Lonza, Verviers, Belgium). CD271 expression was analyzed by flow cytometry (FC) with anti-CD271-allophycocyanin (APC) mAb (ME20.4 IgG1; Miltenyi Biotec, Bergisch Gladbach, Germany), and isolation of CD271+ and CD271 cells was carried out by magnetic cell sorting using an LNGFR-APC MicroBead kit (Miltenyi Biotec). The purity of both populations was further analyzed by FC. Cells were replated, and supernatants were collected after 24 h for quantification of interleukin (IL)-6, IL-8, monocyte chemoattractant protein (MCP)-1, matrix metalloproteinase (MMP)-1, MMP-3, and vascular endothelial growth factor (VEGF) by multiplex enzyme-linked immunosorbent assay (ELISA) (RayBiotech, Norcross, GA, USA). To confirm the multipotent differentiation capacity of both CD271+ and CD271 fractions, we performed subcultures under standard fat, bone, or cartilage differentiation conditions that confirmed their multipotential capacity (Additional file 1: Figure S1) [18]. IL-6 concentration was also determined by single, specific ELISA (BioLegend Inc.). SFs cultured at different passages under standard conditions from normal, OA, or RA tissues were also analyzed for CD271 expression by FC.

Synovial SC/T-cell cocultures

Allogeneic T cells were isolated from peripheral blood from healthy donors by Ficoll-Hypaque density gradient centrifugation and negative selection using the Pan T Cell Isolation Kit II (Miltenyi Biotec). One day before coculture, CD271+ and CD271 SCs (5 × 103 cells/well) were seeded into 96-well plates in RPMI 1640/10 % FCS. Purified T cells (5 × 104 cells/well) were labeled with CellVue Claret dye (Sigma-Aldrich) added to SC cultures and stimulated with human T-activator CD3/CD28 Dynabeads (1 bead/5 cells; Invitrogen Dynal, Oslo, Norway). After 24 h, supernatants were collected and IL-2, IL-10, IL-17, and interferon (IFN)-γ production was measured by ELISA (BioLegend Inc.). Proliferation was measured at 72 h by CellVue dye dilution as detected by FC.

Mouse engraftment of CD271+ and CD271 SCs

CD271+ or CD271 SC implants were prepared by suspension of 7.5 × 104 SCs, previously isolated as described above, in 250 μl of Matrigel growth factor reduced matrix (Corning Life Sciences, Bedford, MA, USA). The Matrigel/SC suspension was subcutaneously injected into the backs of NOD scid gamma (NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ [NSG™]; The Jackson Laboratory, Bar Harbor, ME, USA) mice. Six independent experiments with CD271+/CD271 SCs from six different OA membranes were performed. Mice were killed on the seventh day, and the skin containing Matrigel plugs was excised and snap-frozen in Tissue-Tek O.C.T. compound (Sakura Finetek, Alphen aan den Rijn, the Netherlands).

Statistical analysis

Data were analyzed using GraphPad Prism v6.0 software (GraphPad Software, La Jolla, CA, USA). Means were compared by using Kruskal-Wallis, Friedman, or Wilcoxon tests as appropriate. A p value less than 0.05 was considered statistically significant.

Results

Expression of CD271+ in synovial tissues and cell cultures

CD271+ cells were observed by IHC in all types of synovial tissues with a specific perivascular distribution, not restricted to pericytes but as an extended network around small and medium-sized blood vessels (Fig. 1a). The density of CD271+ cells was significantly increased in inflammatory tissues (OA and RA) compared with normal synovial tissues (Fig. 1b). To confirm the fibroblastic identity of synovial CD271+ cells, double-labeling for CD271 and the fibroblast marker hsp47 was performed [4]. We observed that CD271+ cells also expressed hsp47 in all cases, which confirmed that, in synovial tissues, CD271+ cells are fibroblastic cells (Fig. 1c). We also excluded endothelial identity of CD271 cells by double-labeling CD271 and CD31 (Additional file 2: Figure S2).
Fig. 1

Expression of CD271 in synovial tissues. a Immunohistochemical immunoperoxidase labeling of CD271 in normal, osteoarthritis (OA) and rheumatoid arthritis (RA) synovial tissues as indicated (bar, 50 μm). CTRL immunoglobulin G1 isotype control. OA* shows a perivascular area in OA tissue with higher magnification (bar, 20 μm). b CD271 fractional immunostained area in the different groups (mean ± standard deviation). *p = 0.0012 by analysis of variance Kruskal-Wallis with Dunn’s multiple comparisons test. c Labeling of CD271 (red) and heat shock protein hsp47 (green). Arrows indicate double-positive CD271/hsp47 perivascular cells (bar, 20 μm). NS not significant

To examine the presence of CD271+ cells in standard SF cultures, FC analysis of established (passage 3) SF cultures showed expression in a small but variable percentage of cells. A nonsignificant trend toward a higher proportion of CD271+ cells in SF from OA compared with RA or normal synovial tissues was observed (Fig. 2a). We also observed a progressive decrease in the percentage of CD271+ cells in individual SF cultures throughout passages 0–5 (Fig. 2b). Therefore, isolation of CD271+ SC for further studies was carried out in OA synovial cell cultures at passage 0. After magnetic cell sorting, purified cells contained 64 ± 12 % or 4.7 ± 4 % CD271+ cells in the CD271+ or CD271 fraction, respectively (n = 19 sorting experiments).
Fig. 2

CD271+ cells in established synovial fluid (SF) cultures. a Percentage of CD271+ quantified by flow cytometry in passage 3 SF cultures from normal (n = 4), osteoarthritis (OA; n = 8), or rheumatoid arthritis (RA; n = 5) synovial biopsies. b Progressive reduction of CD271+ cells in SF cultures from OA synovial membranes (n = 3) throughout passages 0–5. SC stromal cells

Immunomodulatory properties of CD271+/CD271 SCs

To determine whether synovial CD271+ SCs differentially modulate T-cell effector functions, T cells were stimulated with anti-CD3/anti-CD28 beads in the presence of CD271+ and CD271 cells (1:10 ratio of SCs to T cells). Under these conditions, both CD271+ and CD271 SCs similarly inhibited the proliferation of allogeneic T cells (Fig. 3a).
Fig. 3

T-cell effects and synthesis of inflammatory factors by sorted CD271+ and CD271 stromal cells (SC). a T-cell proliferation at 72 h and cytokine production at 24 h in supernatants of SC/T-cell cocultures stimulated with CD3/CD28 Dynabeads. Data are representative of paired CD271+ and CD271 synovial SCs from nine different synovial tissue donors cocultured with T cells from nine allogeneic donors (mean ± standard error of the mean are indicated). *p < 0.05 by analysis of variance with Friedman and Dunn’s multiple comparisons tests. b Synthesis of inflammatory mediators in 24-h culture supernatants of paired CD271+ and CD271 synovial SC cultures as quantified by multiplex enzyme-linked immunosorbent assay. Graphics represent triplicate samples from three patients with OA (mean ± standard deviation). *p < 0.05 by Wilcoxon test. NS not significant, IL interleukin, IFN interferon, MMP matrix metalloproteinase, MCP-1 monocyte chemoattractant protein 1, VEGF vascular endothelial growth factor

Coculture of T cells with either CD271+ or CD271 SC induced a similar increase in the production of IL-2, IL-17, IFN-γ, and IL-10 cytokines compared with T cells stimulated in the absence of SCs (Fig. 3a).

Production of inflammatory factors by CD271+/CD271 SCs

The production of selected proinflammatory mediators by SCs, including cytokines (IL-6, IL-8, MCP-1), metalloproteases (MMP-1, MMP-3), and angiogenic factors (VEGF), was quantified by multiplex ELISA in 24-h culture supernatants of sorted CD271+/CD271 cells. CD271+ SCs released significantly more IL-6, MMP-1, and MMP-3 than CD271 SCs did (Fig. 3b). A significant 3.1-fold increased production of IL-6 by CD271+ cell cultures was confirmed by single, specific ELISA in an extended set of samples (n = 5) (CD271+ SCs 1006 ± 286.4 pg/ml vs CD271 SCs 320.2 ± 68.3 pg/ml [mean ± standard error of the mean], p < 0.05 by Wilcoxon test). No significant differences in the production of other mediators were observed (Fig. 3b).

CD271+ SCs induce enhanced myeloid recruitment in vivo

To examine the proinflammatory properties of CD271+ SCs in vivo, we implanted isolated CD271 or CD271+ cells in a Matrigel matrix by subcutaneous injection into NSG mice. After 7 days, human SCs persisted in the implants, as demonstrated by antihuman nuclei IHC, and induced abundant cell recruitment into the Matrigel implant. These infiltrating cells were identified as CD11b+ mouse myeloid cells (Fig. 4a and b).
Fig. 4

Analysis of CD271+ and CD271 stromal cell (SC) implants in immunodeficient mice. a Engrafted SCs were identified in Matrigel implants by immunoperoxidase labeling with antihuman nuclei or isotype control (CTRL) (hematoxylin counterstaining; bar, 100 μm). b Identification on infiltrating myeloid cells by phycoerythrin (PE)-CD11b antibody (red) and 4′,6-diamidino-2-phenylindole (DAPI) counterstaining (blue), PE–immunoglobulin G2b isotype control is also shown. c Representative images of sections stained with DAPI from CD271 and CD271+ Matrigel implants (left panel). Quantitative analysis of cellularity (DAPI-positive nuclei per square millimeter) in CD271 and CD271+ implants (right panel). Data are from six different OA synovial membranes, sorted as CD271+ or CD271 SCs and implanted into NSG mice. *p = 0.03 by Wilcoxon test

The cellularity of the infiltrate was highly variable in implants containing SCs from different individuals. However, in a paired analysis, infiltrating cells were significantly increased in the implants of mice engrafted with CD271+ SCs compared with those in mice engrafted with CD271 SCs from the same individual (Fig. 4c).

Discussion

CD271+ SCs were first described in the BM and considered as a network of specialized perivascular cells [15]. Sorted BM CD271+ SCs have shown multilineage differentiation and immunomodulatory properties as unselected BM MSCs [21]. CD271+ SCs have also been described in inflammatory synovial tissues, where a potential role in cartilage repair has been proposed [16, 17, 19]. Our data confirm that, in synovial tissues, a similar perivascular network of CD271+ is present, similar to that previously observed in the BM, and this prompted us to study their potential function in arthritis.

Because BM CD271+ cells have been shown to display ex vivo immunomodulatory properties similar to those of MSCs, we analyzed whether synovial CD271+ cells may also play this function. Our findings demonstrate that both CD271+ and CD271 synovial SCs have similar antiproliferative effects on allogeneic stimulated T cells. Although consistent with previous studies on CD271+ cells, this suggests that this property is not specific to MSCs, because CD271 synovial SCs also serve this immunomodulatory function, consistent with previous studies with other types of human differentiated fibroblasts [22]. We also found a potent, nonspecific stimulatory effect on T-cell cytokine synthesis in both CD271+ and CD271 synovial SCs. This effect was not selective and involved IL-2 and both regulatory (IL-10) and effector (IL-17 and IFN-γ) cytokines. Therefore, although these data confirm MSC-like immunomodulatory properties of synovial CD271+ cells, they are not distinctive of these cells, reinforcing the concept that these properties could be shared by different stromal or fibroblastic cell types [22].

Expansion and phenotypic changes of differentiated SFs characterize chronic arthritic conditions [4]. We also found significant hyperplasia of perivascular CD271+ SCs in both OA and RA inflammatory tissues compared with noninflammatory tissues, which is consistent with previous observations in OA [19]. Interestingly, these cells show an enhanced intrinsic capacity to synthesize the proinflammatory cytokines IL-6 and MMPs ex vivo, suggesting that they could play a pathogenic rather than a protective role in arthritis. Indeed, we confirmed an intrinsically enhanced proinflammatory function of CD271+ SCs resulting in increased myeloid cell infiltration in the absence of additional stimuli in immunodeficient mice. Although analyzed chemokines were not significantly overexpressed by cultured CD271+ cells, myeloid cell recruitment could be secondary to in vivo IL-6 effects such as endothelial activation and induction of chemokine expression [23, 24].

In agreement with this interpretation, a CD271+ perivascular fibroblastic pool present in normal mouse tissues has been shown to expand and contribute to inflammation and scarring upon tissue injury [25]. Therefore, CD271+ might identify a reservoir of perivascular SCs with enhanced inflammatory mediator synthesis that expands in arthritis. However, due to limited CD271+ cell availability from RA tissues, we analyzed only cultured OA cells and therefore potential differences between OA and RA CD271+ SC cannot be discarded.

Systemic intravenous administration of allogeneic or xenogeneic MSCs has been shown to ameliorate immunomediated inflammation in different experimental models, including collagen-induced arthritis in mice [26]. Whether such an effect is mediated by their homing into the inflamed tissues is unclear [27]. So far, no studies have assessed whether synovial homing contributes to the effect of systemic infusion of different types of SCs, including SF in arthritis. Our data do not support a local protective or anti-inflammatory role for CD271+ SCs. The observed expansion in OA and RA synovial tissues might rather contribute to inflammatory mediator synthesis and myeloid cell infiltration. This suggests that different types of synovial SCs, including CD271+ cells or differentiated pathogenic SF, may have overlapping functions in arthritis. Improved knowledge of the relationship between different synovial SC populations is needed to understand their participation in arthritic diseases.

Conclusions

CD271+ SCs with a perivascular distribution are present in all synovial tissues and expand in inflammatory conditions (RA and OA). CD271+ and CD271 SCs have similar immunomodulatory properties ex vivo, whereas CD271+ cells show enhanced proinflammatory features ex vivo and in vivo. These observations provide a better understanding of the diverse contributions of different synovial SC subpopulations in arthritic diseases.

Abbreviations

APC: 

allophycocyanin

BM: 

bone marrow

DAPI: 

4′,6-diamidino-2-phenylindole

ELISA: 

enzyme-linked immunosorbent assay

FC: 

flow cytometry

FCS: 

fetal calf serum

hsp: 

heat shock protein

IF: 

immunofluorescence

IFN-γ: 

interferon-γ

IgG: 

immunoglobulin G

IHC: 

immunohistochemistry

IL: 

interleukin

mAb: 

monoclonal antibody

MCP-1: 

monocyte chemoattractant protein 1

MMP: 

matrix metalloproteinase

MSC: 

mesenchymal or stromal stem cell

NGFR: 

nerve growth factor receptor

NS: 

not significant

OA: 

osteoarthritis

PE: 

phycoerythrin

RA: 

rheumatoid arthritis

SC: 

stromal cell

SF: 

synovial fibroblast

TNF-α: 

tumor necrosis factor-α

VEGF: 

vascular endothelial growth factor

Declarations

Acknowledgments

We are grateful to Vanessa Miranda for technical assistance. This work was supported by Instituto de Salud Carlos III (FIS12/439, RETICS RD12/009 RIER, Río Hortega program [to RF] and Miguel Servet program [to GC]) and was cofinanced by FEDER and Comunidad de Madrid (RAPHYME-CM S2010/BMD2350).

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (i+12)
(2)
Unitat d’Artritis, Servei de Reumatologia, Hospital Clínic de Barcelona
(3)
Institut d’Investigacions Biomèdiques August Pí i Sunyer
(4)
Servicio de Cirugía Ortopédica y Traumatología, Hospital 12 de Octubre

References

  1. Parsonage G, Filer AD, Haworth O, Nash GB, Rainger GE, Salmon M, et al. A stromal address code defined by fibroblasts. Trends Immunol. 2005;26:150–6.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Buckley CD, Filer A, Haworth O, Parsonage G, Salmon M. Defining a role for fibroblasts in the persistence of chronic inflammatory joint disease. Ann Rheum Dis. 2004;63(Suppl II):ii92–5.PubMedPubMed CentralGoogle Scholar
  3. Bottini N, Firestein GS. Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. Nat Rev Rheumatol. 2013;9:24–33. doi:10.1038/nrrheum.2012.190.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Izquierdo E, Cañete JD, Celis R, Del Rey MJ, Usategui A, Marsal S, et al. Synovial fibroblast hyperplasia in rheumatoid arthritis: clinicopathologic correlations and partial reversal by anti–tumor necrosis factor therapy. Arthritis Rheum. 2011;63:2575–83. doi:10.1002/art.30433.View ArticlePubMedGoogle Scholar
  5. Klein K, Gay S. Epigenetic modifications in rheumatoid arthritis, a review. Curr Opin Pharmacol. 2013;13:420–5. doi:10.1016/j.coph.2013.01.007.View ArticlePubMedGoogle Scholar
  6. Nakano K, Whitaker JW, Boyle DL, Wang W, Firestein GS. DNA methylome signature in rheumatoid arthritis. Ann Rheum Dis. 2013;72:110–7. doi:10.1136/annrheumdis-2012-201526.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Lee A, Qiao Y, Grigoriev G, Chen J, Park-Min KH, Park SH, et al. Tumor necrosis factor α induces sustained signaling and a prolonged and unremitting inflammatory response in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum. 2013;65:928–38. doi:10.1002/art.37853.View ArticlePubMedPubMed CentralGoogle Scholar
  8. MacFadyen JR, Haworth O, Roberston D, Hardie D, Webster MT, Morris HR, et al. Endosialin (TEM1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium. FEBS Lett. 2005;579:2569–75.View ArticlePubMedGoogle Scholar
  9. Kiener HP, Lee DM, Agarwal SK, Brenner MB. Cadherin-11 induces rheumatoid arthritis fibroblast-like synoviocytes to form lining layers in vitro. Am J Pathol. 2006;168:1486–99.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Del Rey MJ, Faré R, Izquierdo E, Usategui A, Rodríguez-Fernández JL, Suérez-Fueyo A, et al. Clinicopathological correlations of podoplanin (gp38) expression in rheumatoid synovium and its potential contribution to fibroblast platelet crosstalk. PLoS One. 2014;9, e99607. doi:10.1371/journal.pone.0099607.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Gebler A, Zabel O, Seliger B. The immunomodulatory capacity of mesenchymal stem cells. Trends Mol Med. 2012;18:128–34. doi:10.1016/j.molmed.2011.10.004.View ArticlePubMedGoogle Scholar
  12. Bianco P, Cao X, Frenette PS, Mao JJ, Robey PG, Simmons PJ, et al. The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nat Med. 2013;19:35–42. doi:10.1038/nm.3028.View ArticlePubMedPubMed CentralGoogle Scholar
  13. De Bari C, Dell’Accio F, Tylzanowski P, Luyten FP. Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum. 2001;44:1928–42.View ArticlePubMedGoogle Scholar
  14. Jones EA, English A, Henshaw K, Kinsey SE, Markham AF, Emery P, et al. Enumeration and phenotypic characterization of synovial fluid multipotential mesenchymal progenitor cells in inflammatory and degenerative arthritis. Arthritis Rheum. 2004;50:817–27.View ArticlePubMedGoogle Scholar
  15. Cattoretti G, Schiro R, Orazi A, Soligo D, Colombo MP. Bone marrow stroma in humans: anti-nerve growth factor receptor antibodies selectively stain reticular cells in vivo and in vitro. Blood. 1993;81:1726–38.PubMedGoogle Scholar
  16. Jones E, English A, Churchman SM, Kouroupis D, Boxall SA, Kinsey S, et al. Large-scale extraction and characterization of CD271+ multipotential stromal cells from trabecular bone in health and osteoarthritis: implications for bone regeneration strategies based on uncultured or minimally cultured multipotential stromal cells. Arthritis Rheum. 2010;62:1944–54. doi:10.1002/art.27451.View ArticlePubMedGoogle Scholar
  17. Van Landuyt KB, Jones EA, McGonagle D, Luyten FP, Lories RJ. Flow cytometric characterization of freshly isolated and culture expanded human synovial cell populations in patients with chronic arthritis. Arthritis Res Ther. 2010;12:R15. doi:10.1186/ar2916.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Arufe MC, De la Fuente A, Fuentes I, de Toro FJ, Blanco FJ. Chondrogenic potential of subpopulations of cells expressing mesenchymal stem cell markers derived from human synovial membranes. J Cell Biochem. 2010;111:834–45. doi:10.1002/jcb.22768.View ArticlePubMedGoogle Scholar
  19. Hermida-Gómez T, Fuentes-Boquete I, Gimeno-Longas MJ, Muiños-López E, Díaz-Prado S, de Toro FJ, et al. Bone marrow cells immunomagnetically selected for CD271+ antigen promote in vitro the repair of articular cartilage defects. Tissue Eng Part A. 2011;17:1169–79. doi:10.1089/ten.TEA.2010.0346.View ArticlePubMedGoogle Scholar
  20. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.View ArticlePubMedGoogle Scholar
  21. Kuçi S, Kuçi Z, Kreyenberg H, Deak E, Pütsch K, Huenecke S, et al. CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. Haematologica. 2010;95:651–9. doi:10.3324/haematol.2009.015065.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Haniffa MA, Wang XN, Holtick U, Rae M, Isaacs JD, Dickinson AM, et al. Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells. J Immunol. 2007;179:1595–604.View ArticlePubMedGoogle Scholar
  23. Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, et al. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity. 2001;14:705–14.View ArticlePubMedGoogle Scholar
  24. McLoughlin RM, Hurst SM, Nowell MA, Harris DA, Horiuchi S, Morgan LW, et al. Differential regulation of neutrophil-activating chemokines by IL-6 and its soluble receptor isoforms. J Immunol. 2004;172:5676–83.View ArticlePubMedGoogle Scholar
  25. Dulauroy S, Di Carlo SE, Langa F, Eberl G, Peduto L. Lineage tracing and genetic ablation of ADAM12+ perivascular cells identify a major source of profibrotic cells during acute tissue injury. Nat Med. 2012;18:1262–70. doi:10.1038/nm.2848.View ArticlePubMedGoogle Scholar
  26. El-Jawhari JJ, El-Sherbiny YM, Jones EA, McGonagle D. Mesenchymal stem cells, autoimmunity and rheumatoid arthritis. QJM. 2014;107:505–14. doi:10.1093/qjmed/hcu033.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Sala E, Genua M, Petti L, Anselmo A, Arena V, Cibella J, et al. Mesenchymal stem cells reduce colitis in mice via release of TSG6, independently of their localization to the intestine. Gastroenterology. 2015;149:163–76.e20. doi:10.1053/j.gastro.2015.03.013.

Copyright

© Del Rey et al. 2016

Advertisement